Results 161 to 170 of about 97,595 (299)
ABSTRACT The recent fifth edition WHO classification and ICC classification systems have moved further toward genetically defined classifications of acute leukemias. Both now recognize myelodysplasia‐related (MR) mutations as defining of MDS‐related AML (AML‐MR).
Timothy J. Kirtek, Olga K. Weinberg
wiley +1 more source
Spectrum of Chromosomal Abnormalities in Abortus and Medically Terminated Fetal Samples From a Tertiary Care Center in the Sub-Himalayan Region of North India. [PDF]
Malhotra R +9 more
europepmc +1 more source
ABSTRACT Hematologic emergencies are urgent health conditions which result in significant mortality and morbidity unless timely therapeutic measures are taken. Therapeutic success depends on their timely and accurate recognition by hematology laboratory services.
Ganna Shestakova +2 more
wiley +1 more source
Transcription Factors GATA1/2 in Hematological Disorders. [PDF]
Karr M, Palmisiano N, Chen X.
europepmc +1 more source
ABSTRACT Background Healthcare decision‐making for individuals with rare genetic neurodevelopmental disorders (RGNDs) associated with intellectual disabilities (ID) can be complex due to the intersection of lifelong care needs, limited medical expertise and communication barriers.
Mirthe J. Klein Haneveld +6 more
wiley +1 more source
Erythema Nodosum Associated with Myelodysplastic Syndrome: A Case Report [PDF]
Adam, Christian +3 more
core +1 more source
ABSTRACT Unquestionably, with the increase in life expectancy, dementia has become a significant health issue in Down syndrome (DS). However, in at least a subset of these individuals, cognitive aging can be considered normal, with absence of dementia symptoms even in the presence of Alzheimer's neuropathology.
Livea Carla F. G. Sant'Ana +3 more
wiley +1 more source
Detection of Down syndrome by in situ hybridization with chromosome 21 specific DNA probes [PDF]
Cremer, Thomas +4 more
core
Clinical Use of Combined First-Trimester Screening Test for Aneuploidy in A Low-Income Setting: Retrospective Study. [PDF]
Diress T +4 more
europepmc +1 more source
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy
Abstract Background ASXL1 mutations (ASXL1MUT) are common in acute myeloid leukemia (AML) and have historically conferred an adverse prognosis with intensive chemotherapy. Given the increasing use of venetoclax (VEN)‐based lower intensity therapy (LIT), the European LeukemiaNet introduced a four‐gene genetic risk classifier in 2024 that categorizes ...
Jennifer Marvin‐Peek +26 more
wiley +1 more source

